Still Waiting

Fiscal cliff, Phase 2 results, and partners. No good news today.............. Geron down 1 cent to $1.59 on light volume of 771,484. The three month avg. volume is 1.1 million ,,,,,,,,ACTC 0.0615 up a little on 8.6 million shares. The three month avg. volume is 6.2 million shares. ...Good luck in this rigged casino,

Good News for ACTC

MARLBOROUGH, Mass., Dec 20, 2012 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC or the "Company"), a leader in the field of regenerative medicine, today announced that its iPS cell-derived human platelet program has been named as one of the "10 Ideas That Will Shape The Year" in the 'Christmas and New Year Special' issue of the New Scientist, widely considered to be one of the most influential science and technology news magazines in the world. The list includes innovations in different scientific areas such as health and medicine, climate change, technology and others. ACT's platelet program aims to provide a renewable, donorless source of blood platelets to people in need of platelet transfusions. "Human iPS cells are a game-changer in medicine," said Robert Lanza, M.D., chief scientific officer of ACT. "They offer the possibility to generate a non-controversial, unlimited source of patient-specific stem cells without embryo destruction. Owing to their short storage time, there is a constant demand for this life-saving blood component. Since platelets don't contain any genetic material, they cannot form tumors, which makes them ideal for the first clinical trial involving the iPS cell technology. We hope to initiate the first clinical trial using these promising cells in 2013." ACT plans to compare normal and iPS cell-derived platelets in eight healthy volunteers and analyze recovery and survival. Additionally, normal platelets will be compared to human embryonic stem cell-derived platelet cells. "We appreciate this recognition from the New Scientist," commended Gary Rabin, chairman and CEO. "It speaks to the growing importance of the stem cell and regenerative medicine sector." ACTC is up just a little............................................................... .................................................................................................................................................................................Good luck in this rigged casino,

Waiting

It's just a waiting game, the fiscal cliff, the Phase 1/2 results and year end bouses. ......................................................................................................................................................................................................................................................................Geron closed at $1.60 up 2 cents. Volume was only 822,874 shares. The three month avg. is 1.2 million shares. Some people think they will get a buy out. What is there then to buy?........................................................................... ...............................................................................................................................................................................ACTC under 6 cents again at 0.0595 on 13.6 million shares. The three month avg. is 6.5 million shares.................................................................... ......................................................................................................................................................................................BTX closed at $3.50 I still think if they get Geron's stem cell property. They will be the furture in bio tech. They will need $500,0000,0000 to finish the trials.. ......................................................................................................................................................................................................................................................................AAPL closed at $526.31 down $7.59 on only 15.7 million shares. The three month avg. volume is 21.8 million shares. Hoping for a run the $625 in Jan 2013. ................. ...................................................................................................................................................................................Good luck in this rigged casino,

ACTC moving ahead with Phase 1/2 trials

Good news for ACTC, the trial is now half over and will be finished in 2013. That news got ACTC over 6 cents to close at 0.061 on 9.6 million shares. The three month avg. is 6.6 million shares. ................................................................... ....................................................................................... Welcome to my nightmare, after I sold most of my Geron shares [at around $1.35] it's up and closed at $1.70. Yea if it wasn't for bad luck I'd have no luck at all....... ............................................................................................................................................................................. AAPL I think is done going down, the last time I said that it went down 30 more point. AAPL closed at $518.83 up $9.04 ON 26.9 MILLION SHARES. The three month avg. is 21.4 million shares. ..................................................................... ................................................................................................................................................................................Good luck in this rigged casino,

Geron up again

Will Geron was up 3 days in a row, good sign, it closed at $1.42 up 3 cents, on 2+ million shares. The three month avg. is 1.2 million shares. ........................... ................................................................................................................................................................................ACTC still going down slowly closed at 0.055, on 5.2 million shares. The three month aavg. volume is 6.5 million shares.................................................... ............................................................................................................................................................................. BTX closed down 6 cent at $3.42 on only 36,571 shares. The three month avg. volume is 90,552 shares. ....................................................................... ...............................................................................................................................................................................AAPL down $2.39 at $539.00. AAPL should be going up, with Apple TV coming[maybe] and China buying all those iPhone......................................................... Good luck in this rigged casino,

Geron up

Geron went up 17 more cents to close at $1.39 on 3.7 million shares. The three month avg. is 1.3 million. The avg days up for most stocks is three days, then a little pull back and then if the move is real the stock will go up again, if not down. This is the 3rd day, lets see what happens......................................................... ....................................................................................... ....................................................................................... .....................................................................................................................................................................................................................................................................ACTC just keeps going down may add a few shares under 5 cents........................ .............................................................................................................................................................................................................................................................................................................................................................BTX I started a postion with 100 shares. I feel they may be the next big thing. I thought that about Geron and lost my ass.............................................. ....................................................................................... ....................................................................................... .....................................................................................................................................................................................................................................................................AAPL looks like it's done going down closed at $541.39 up $11.57 on normal volume... ...........................................................................................................................................................................................Good luck in this rigged casino,

Geron up 15%

Geron closed up 16 cents at $1.22 on 6+ million shares. The three month avg. is 1.5 million shares. I sold all but 1,700 shares. Geron in the past never holds the gains for long. Lets see if it holds Monday's gains.......................................... .............................................................................................................................................................................. ACTC down under 6 cent, we go lower with no good news, no reverse split and no partner. ...................................................................................................................................................................................BTX was up 16 cents to close at $3.44, had a order in, but didn't hit my price. If BTX gets Geron's stem cell property, I'm going to change title of blog to BioTime the furture in bio tech. I checked there website and they are in it big time with seven different companies. The problem, they all are losing money...................... .............................................................................................................................................................................. Good luck in this rigged casino,

Geron Positive Results from Phase 2 Study of Imetelstat

MENLO PARK, Calif., December 10, 2012 - Geron Corporation (GERN) today announced positive clinical results from the Phase 2 trial of imetelstat, the company`s first-in-class telomerase inhibitor, in patients with essential thrombocythemia (ET). ET is a chronic blood disorder that is representative of a group of diseases known as myeloproliferative neoplasms (MPNs). The data, which showed rapid and durable hematologic and molecular responses in patients treated with imetelstat, were presented Sunday evening in an oral session at the 54th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, GA, by Prof. Dr. med. Gabriela M. Baerlocher of the University Hospital and University of Bern, Switzerland, and a principal investigator of the trial. To view the presentation slides, please visit www.geron.com/PDFs/Geron-Imetelstat-ETPh2-ASH-2012.pdf. .............................. ...............................................................................................................................................................................I sold most of my shares in Geron, will put most of the money in IBB and DVY. Geron is up 29% at $1.37. The results are good but it will take 2-3 years at least to bring to market, and the market for ET is small. Also I don't believe in Geron management. Plus I'm old and will be retiring soon, need income and stable share price. ........... ...............................................................................................................................................................................Good like in this rigged casino,

Geron is a Train Wreck

Shares fell 20% when it gave up on development of treatments using stem cells last year and an additional 56% earlier this year when its lead cancer drug, imetelstat, failed a phase 2 trial in breast cancer. And now it's down 25% today after disclosing that its (now lead) drug GRN1005 failed to show an effect on brain metastases in patients with breast cancer. What's left? Imetelstat. While it was hit by an oncoming train, it appears the drug wasn't completely knocked off the track. Geron blamed the lack of success in breast cancer patients on overlapping toxicities of imetelstat and a chemotherapy it was combined with, which led doctors to decrease the chemotherapy dose. The biotech also stopped a lung cancer trial where imetelstat was used as a single agent because it appeared that any effect Geron might see wouldn't be statistically significant. As it had planned to do after the trial ended, Geron looked at patients with tumors that had short telomeres -- the protective ends of chromosomes -- and found patients in that subgroup taking imetelstat progressed slower than those on placebo. The data are only from 19 patients, but the finding makes sense scientifically. Imetelstat is designed to inhibit the enzyme responsible for lengthening telomeres. Giving the drug a head start by starting with short telomeres would make it easier for the drug to kill the tumor cell. Geron also has data from a phase 2 trial in patients with essential thrombocythemia, a blood cancer, where 100% of the patients had a response with 13 out of the 14 patients achieving a complete response. These are patients that failed or couldn't take other therapies, so any response is pretty impressive. .............................................................................................................................................................................. That was from Motley Fool's website.................................................... Geron hit a new low of .91 and closed at $1.14 on 6+ million shares. The three month avg. is 1.5 million shares........................................................... ........................................................................................My Wife was so upset, she sold all her Geron shares at market, for 94 cents a shares. Told me when the money clears, close the IRA account, take all the money out. If I don't stop losing money by 2014, I'm going to do the same thing. The average investor doesn't stand a chance. It's a rigged casino. I can make more money buying junk and reselling it, which I enjoy doing.

Geron unbelievable 1 out of 6 trials postive

MENLO PARK, Calif., December 3, 2012 - Geron Corporation (GERN) today announced that the company has discontinued development of GRN1005, its peptide-drug conjugate designed to treat cancers in the brain. Going forward, the company will focus on the development of imetelstat, its telomerase inhibitor, in hematologic myeloid malignancies and in patients with solid tumors that have short telomeres. The company also announced a restructuring to reduce its workforce from 107 positions to 64 full-time positions, and to reduce its annual cash operating expenses from approximately $65 million in 2012 to approximately $33 million in 2013, which includes non-recurring costs of approximately $3 million associated with the restructuring and approximately $3 million for the discontinuation of clinical trials. The company expects to end 2012 with approximately $90 million in cash and investments................................. ....................................................................................... Only one phase 2 trial out of six has positve results. The one trial of Imetelstat it's drug to treat essential thrombocytosis [ET] and certain types of tumors............... ...................................................................................... Geron was down over 20% afterhours. Will start selling a little each week after Dec 9th when Chip will say a few more words about his plans for Geron...................... This is a disaster..................................................................... ......................................................................................................................................................................................................................................................................Good luck in this rigged casino,

Geron ACTC AAPL all down

No news on Geron, ACTC and BTX. All down a little. Geron down 3 cents at $1.41. ACTC closed at 0.0613, we'll see 5 cent soon with no news. BTX down 5 cents at $3.59. AAPL down $4.08 at $585.28. AAPL will soon be selling new iPhones in China, should move price up, if they sell like hotcakes................................................... ................................................................................................................................................................................Good luck in this rigged casino,

BioTime up

I don't get why BioTime is moving up. Maybe the Geron deal is a deal for BioTome. The cost to bring the stem cell program to Phase 3 would be around $200-300 million give or take $100 million. Bio Time does not have it. BTX closed up at $3.64 on avg volume................................................................................ ...................................................................................... Geron up 2 cent at $1.44 on light volume. I've bought back most of my $2 Mar 13 calls. Thinking good news early in Dec 5-7. ............................................... ............................................................................................................................................................................. ACTC down a litte to close at 0.0621. Need good results on Phase 1/2.................. .............................................................................................................................................................................. AAPL slowly moving up closed at $589.36. Need $100 more for my calls, but will sell some at $625......................................................................... Good luck in this rigged casino.

ACTC Announces Completion of Higher Dosage

ACT Announces Completion of Higher-Dosage Cohort in Both U.S. Clinical Trials Three Patients with Forms of Macular Degeneration Injected with 100,000 hESC-Derived RPE Cells, Successfully Completing Second Cohort...................................... ......................................................................................................................................................................................................................................................................Great news for ACTC closed at 0.0622. Need results and a partner with lots of money. . ......................................................................................................................................................................................................................................................................Geron closed up 4 cent at $1.42 on light volume. I would think we should run up more before results of Phase 2 trials............................................... ............................................................................................................................................................................. BTX closed up 6 cents on light volume. It's hard to believe this company will get Geron's stem cell property for pennies on the dollar. Soon I will be adding BioTime as the future of bio tech.............................................................. Good luck in this rigged casino,

HP was duped in Autonomy Deal

Not going to say much about Geron, ACTC and AAPL today. Let's look at this rigged casino. HP paid 10 billion dollars about a year ago for Autonomy and guess what the company is worth only 1 billion dollars. You would think the people running HP would know what the value of the company was. You would think someone at Autonomy would know someone was cooking the books. After 30 years of investing, I can say that was my biggest mistake "investing" [and I've made many many many big mistakes]. You should only invest if you have inside infor. Because the market is a rigged casino and the average investor doesn't stand a chance................................................ Good luck in this rigged casino.

BTX up big, Geron up

The market must like BTX's Stem Cell deal with Geron. BTX is up 46 cents or 15% at $3.51 on 389,396 shares the three month avg. is 82,711 shares. ............................. ..................................................................................................................................................................................................................................................................... Geron closed up 7 cents at $1.32 on only 556,757 shares. .............................. ..................................................................................................................................................................................ACTC closed at 0.064, volume was 5.4 million shares. If the reverse split does not happen soon and there is no good news, we go to 5 cents................................ ..................................................................................................................................................................................................................................................................... AAPL moved up big time to close at $565.73, need a $100 run just to break even on my calls............................................................................... Good luck in this rigged casino,

BioTime like deal Geron not so much

Geron was up 4 cents and closed at $1.25 on only 537,556 shares the 3 month avg volume is 1.7 million shares. BioTime was up 8 cents on 141,710 shares the 3 month avg volume is 82,265 shares. I'm hoping for a better deal. Geron spent about $500,000,000 on there stem cell program. They are getting maybe $40 million, what a deal,,,,for BioTime. ............................................................................................................................................................................................................................................................ ACTC closed at 0.064 on 6.3 million shares the three month avg volume is 5.8 million sshares. Need good news................................................... .............................................................................................................................................................................. AAPL I think hit bottom today and closed at $527.68 on 44.8 million shares. The three month avg. is 19 million shares. .................................................... ..................................................................................................................................................................................................................................................................... Good luck in this rigged casino,

Geron Announces Non-Binding Letter of intent with BTX

MENLO PARK, Calif., November 15, 2012 -- Geron Corporation (Nasdaq: GERN) today announced that the company has entered into a non-binding letter of intent (LOI) with BioTime, Inc. (NYSE: BTX) and BioTime's recently formed subsidiary, BioTime Acquisition Corporation (BAC). The LOI contains broad terms of a potential transaction through which Geron would contribute to BAC its intellectual property and other assets related to Geron's discontinued human embryonic stem cell programs. BioTime would contribute to BAC $5 million in cash, $30 million of BioTime common shares, warrants to purchase eight (8) million shares of BioTime at a pre-specified price (the "BioTime Warrants"), rights to use certain human embryonic stem cell lines, and minority stakes in two of BioTime's subsidiaries. Following consummation of the potential transaction, Geron stockholders would receive shares representing 21.4% of the common stock of BAC as well as warrants to purchase eight (8) million shares of BioTime common stock at a pre-specified price. BioTime would own approximately 71.6%, and a private investor would own approximately 7.0% of the outstanding BAC common stock for an additional $5 million investment. BioTime would also receive warrants that would enable it to increase its ownership in BAC by approximately 2%, which would dilute the Geron stockholders' ownership in BAC to 19.2%. BAC would also be committed to pay to Geron royalties on the sale of products that are commercialized in reliance upon Geron patents acquired by BAC. The LOI and its broad terms are not binding. Consummation of the transaction is necessarily subject to entering into a definitive agreement between the parties containing specific signing and closing terms and conditions yet to be negotiated. Stifel Nicolaus Weisel is acting as financial advisor and Weil, Gotshal & Manges LLP is acting as legal counsel to Geron in connection with the divestiture of Geron's stem cell assets. What does Geron shareholders get dollar wish next to nothing. When BTX made there move there share pric was over $4 NOW IT'S UNDER $3. But a little money is better then nothing and more important the science will go forward. Geron closed at $1.21 on only 402,999 shares.......................................... ..................................................................................................................................................................................................................................................................... ACTC down 0.0648 on 5.5 million shares................................................ .............................................................................................................................................................................. AAPL is killing me at may go under $500 which is just crazy. Closed at $525.62......... Good luck in this rigged casino,

Geron and ACTC down

AAPL up 7 whole cent to $542.90 on 19 million shares. The three month avg volume is 18.5 million shares. The fiscal cliff is holding the market back. The longer it takes to fix the lower we go. If they can fix it fast, up up up we go. .................................................................................... ACTC down under 7 cents at 0.0685 on 5.8 million shares. Waiting for results on Phase 1/2 trials......................................................................... ..................................................................................................................................................................................................................................................................... Geron down to $1.24 on only 635,399 shares. Around Dec 5th Chip will tell us about all the Phase two trials. If it's good we run up to $2-$3, if bad, it's over............. Good luck in this rigged casino,

Depressing AAPL and Geron down, ACTC up on good news

What a depressing market. AAPL down down down to $537.75 on alot of volume 37.7 million shares. The three month avg. is 17.6 million shares. AAPL is still the best company out there, for now, makes you think what in the world is going on. ..................................................................................................................................................................................................................................................................... Geron down to $1.28 I can only hope Dec. will being good results the the last 4 trials. If I will be sitting here crying........................................ ..................................................................................................................................................................................................................................................................... ACTC had good news on was up a little at 0.072. Advanced Cell Tech. announces interim data from its three ongoing macular degeneration trials; no adverse safety issues relating to the transplanted cells have been observed (ACTC) 0.07 +0.00 : Co announced that its upcoming conference call on its third quarter financial results will also provide some representative examples of data being collected from patients in its clinical trials for forms of macular degeneration. The Company has treated 13 patients thus far in its three ongoing trials for dry age-related macular degeneration (dry AMD) and Stargardt's Disease (SMD) using human embryonic stem cell (hESC)-derived retinal pigment epithelial cells. The first two trials were initiated in July of 2011. Across the various clinical trial sites, with regular patient follow-up, no adverse safety issues relating to the transplanted cells have been observed. At up to 16 months following treatment, no hyperproliferation, tumorigenicity, ectopic tissue formation, or apparent rejection were observed in any of the 13 patients at any time. At a recent meeting of the various U.S. and U.K. surgeons leading the clinical trials, the Company and surgeons reviewed the data from various patients and discussed next steps and strategies for the existing trials and designs for future phase II and III studies..............................................I still have a good feeling about this company. It's a very, very long shot.............................................. .............................................................................................................................................................................. Good luck in this rigged casino,

Geron and AAPL killing me

Geron down 6 cent to close at $1.31 on only 453,489 the ten day avg is 789,925 shares. Waited for Phase two trial results in early Dec. Again this will make or break this company............................................................................... ..................................................................................................................................................................................................................................................................... AAPL is a big disappointment, didn't hold $600 and may go to $550. Closed down a little at $582.85. Christmas may save AAPL............................................. ..................................................................................................................................................................................................................................................................... ACTC up over 7 cents to closed at 0.0727 on 5.8 million shares the ten day avg is 4.4 million shares. Still feel this company will make it big, with little luck............ ..................................................................................................................................................................................................................................................................... Good luck in this rigged casino,

Geron good article by Ivan Deryigin

I could have sold my shares in September and walked away with profits of almost 70%, and that would have been the end of it. However, I chose not to do that. And the reason is simple. This was, and is, an investment only for risk tolerant investors, who have room for speculation in their portfolios. And I consider this investment to be, at the moment, a speculative one. When I wrote my original article, I stated that Geron has the potential to change the way that cancer is treated, due to its focus on telomerase inhibition and brain tumors. I stand by that opinion. The failure of imetelstat in solid tumors has not affected the company`s hematologic trials, nor has it affected the development of GRN-1005, which has the potential to create a truly effective treatment for brain metastases, something that has eluded cancer researchers and pharmaceutical companies for years, due to the blood-brain barrier and the difficulty of getting cancer medications across it. While Geron does have the potential to change the way that cancer is treated, the path ahead is an uncertain one, and this stock is not meant for all investors. But, for investors who are willing to take the risk, Geron continues to offer the opportunity for profits, with the next catalyst just a month away. Above is a small part of the article. This is the guy who pumped it up in Sept. up to $2.99. I hope he can do it again. With good results we should go to $3, with poor results it's all over. Geron is up 7 cents on this article. Good luck in this rigged casino,

All down ACTC AAPL Geron

Bad day, AAPL down big closing at $576.80, ACTC down under 7 cents, and Geron down 7 cents at $1.32......., ............................................................... ............................................................................................................................................................................. Nothing good will happen till after the election and the fiscal cliff is fixed......... .................................................................................................................................................................................................................................................................... Good luck in this rigged casino,

Geron up, ACTC up and AAPL up

Geron was up 6 cents on very light volume only 560,143 shares. The three month avg is 1.6 million shares. Remember Chip said in a few days Geron will file a SEC 10-K report on the BioTime deal. BioTime was down 14 cents to $3.67 just a week ago it was over $4. The volume was 2xs the normal. Based on BioTime's price drop and volume I'm thinking Geron may take the deal, I hope GE makes a offer. Time was tell. ..................................................................................................................................................................................................................................................................... ACTC closed at 7 cents on avg. volume. Still waiting on results of Phase 1/2 trials should be in 3 to 6 months. .................................................................................................................................................................................................................................................................... AAPL up just a little to close at $596.54. Hoping people buy 10 million mini Ipods for the holidays......................................................................... ..............................................................................................................................................................................Good luck in this rigged casino,

Geron Earning Call

Well I read the earnings call and learned next to nothing. Upset about no infor on the stell cell deal. Chip did say in a few days will file a SEC 10-K about the BioTime deal. Chip said reports of Phase 2 trials will be coming in Dec. Again this will make or break Geron. I have no good or bad feeling about up coming reports. Good luck in this rigged casino,

ACTC gets OK for 2nd Patient Cohort in Trials for Dry AMD

Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the Data and Safety Monitoring Board (DSMB), an independent group of medical experts closely monitoring the Company's three ongoing clinical trials, has authorized the Company to move forward with enrollment and treatment of two additional patients with dry age-related macular degeneration (dry AMD). ACT will screen and enroll the second and third patients of the three-patient second cohort in the trial. Per trial protocol, each patient will be injected with 100,000 human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells. "Dry AMD represents one of the largest unmet medical needs in the world, and we are thrilled to be making steady progress in our clinical trial for this condition," commented Gary Rabin, ACT's chairman and CEO. "We are well on our way to the halfway point of all three of our clinical trials. We also recently secured DSMB approval to complete the second cohort of our two trials for Stargardt's Macular Dystrophy." ACT is conducting three clinical trials in the U.S. and Europe using hESC-derived RPE cells to treat forms of macular degeneration, dry AMD and Stargardt's Macular Dystrophy (SMD). Each trial will enroll a total of 12 patients, with cohorts of three patients each in an ascending dosage format, from 50,000 to 200,000 hESC-derived RPE cells. These trials are prospective, open-label studies, designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation into patients with dry AMD or SMD at 12 months, the study's primary endpoint. "This authorization to treat the next two patients in the second, higher-dosage cohort of our trial for dry AMD represents a notable milestone for our clinical programs," commented Robert Lanza, M.D., ACT's chief scientific officer. "We look forward to treating these two patients and moving on to the third cohort in good time." Good news trials moving forward. Good luck in this rigged casino,

Working till I drop over dead thanks AAPL

AAPL missed earnings est. but just a little. I'll sell the three calls one at a time, one in Dec, Jan and Feb, hoping I can cut the loss to 40% which is still a big loss. AAPL closed down $5.54 at $604 alot of volume 36.7 million shares. The three month avg. volume is 16.7 million shares. ................................................... .............................................................................................................................................................................. Geron up 3 cents at $1.30 volume a little better at 1.2 million shares. Dec, Geron will tell us how the last 4 Phase two trials are going. If there is any run up I'm sell 5 thousand shares. Geron as been batting zero I can't lose more money on this company. .............................................................................................................................................................................. ACTC down a little at 0.0701 on 4.4 million shares. Need news or we go lower........... .............................................................................................................................................................................. Good luck in this rigged casino,

AAPPL, ACTC and Geron all up

AAPL was up $3.47 to close at $616.83 on 19.8 million shares. Thursday is the make or break day for my calls. Need blow out earnings and a $50+ run up....................... .....................................................................................................................................................................................................................................................................ACTC up a little at 0.0710. Only 3.9 million shares the three month avg. volume is 5.7 million shares. With no news we go lower. May buy a little under 7 cents............... ............................................................................................................................................................................................................................................................................................................................................................ Geron no news on the deal, I'm betting Chip will tell all Oct 30th at 4:30PM it will be webcast, earninngs call. Geron closed at $1.34 up 2 cents volume was only 405,164 shares. There's no interest in this company. Need good news on the last 4 Phase two trials. If no good news we go under $1.....................................................................................May add BTX to my holdings but only 100 shares................................... .......................................................................................Good luck in this rigged casino,

AAPL down big, ACTC and Geron down

AAPL's iPod mini looks great but the $329 price may be to much, so the market thinks. I'm thinking they will sell 10 million+. Down $20.67 to close at $613.36, volume was 25.1 million shares. The three month avg. volume 16.3 million shares. ..................................................................................................................................................................................................................................................................................ACTC down a little at 0.0702, holding 7 cents but not for long without good news. ..................................................................................................................................................................................................................................................................................Geron down a little at $1.32 on 768,621 shares. No word on the BioTime deal..................................................................................................................................................................................................................................................................Good luck in this rigged casino,

Tom Okarma working for BTX was working for Geron

Dr West is CEO of BioTime and was the founder of Geron. Tom Okarma was hired by Dr. West who also worked at Geron and was a leader in the embryonic movement. Was Geron sell [more like give it to BioTime] it to Dr. West. Maybe. If I remember what I read GE has the right to review any deal and make a deal with Geron. Geron closed down 0.055 cents at $1.38. The volume was low only 452,103 shares ..................................................................................................................................... ..................................................................................................................................................................................................................................................................... ACTC closed down a little at 0.0715. I think we go under 6 maybe by Dec................ ..............................................................................................................................................................................AAPL up big to close at $634.03, need $40 more for my calls. The iPod mini Tue. and earnings Thur.......................................................................... ..............................................................................................................................................................................Good luck in this rigged casino,

ACTC Clinical Trial Advances

Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, today announced treatment of the fourth patient, the first in the second patient cohort, in its European clinical trial for Stargardt’s Macular Dystrophy (SMD). The patient was injected with 100,000 human embryonic stem cell-derived retinal pigment epithelial (RPE) cells, as compared with 50,000 cells in the three patients comprising the first cohort. The outpatient transplantation surgery was performed successfully and the patient is recovering uneventfully. “Our progress continues in our European clinical trial and both our trials in the U.S., as seen most recently with last week’s announcement of treatment of the second patient in the second patient cohort of our U.S. trial for SMD,” said Gary Rabin, chairman and CEO of ACT. “As I mentioned last week, we have mapped out the series of patients to complete the second cohort of both our trials for SMD, as well as for our trial for dry age-related macular degeneration (dry AMD), pending DSMB review, and we anticipate generating patient data at a faster pace.” Initiated in January of this year, the Phase I/II trial is designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation in patients with SMD at 12 months, the study’s primary endpoint. It will involve a total of 12 patients, with cohorts of three patients each in an ascending dosage format. The company is concurrently conducting another trial for SMD and one for dry AMD, both in the U.S. “We are very gratified to be initiating the first treatment of the second patient cohort in our European clinical trial, having just started it this year,” commented Robert Lanza, M.D., ACT’s chief scientific officer. “Our two U.S. trials also continue to move steadily forward.” Further information about patient eligibility for ACT’s SMD study and the concurrent studies in the U.S. and Europe (for dry age-related macular degeneration and SMD, respectively) are available at www.clinicaltrials.gov, with the following Identifiers: NCT01469832 (E.U. SMD), NCT01345006 (U.S. SMD), and NCT01344993 (dry AMD). About Stargardt’s Disease Stargardt’s disease or Stargardt’s Macular Dystrophy is a genetic disease that causes progressive vision loss, usually starting in children between 10 to 20 years of age. Eventually, blindness results from photoreceptor loss associated with degeneration in the pigmented layer of the retina, called the retinal pigment epithelium, which is the site of damage that the company believes the hESC-derived RPE may be able to target for repair after administration........................................................ ..................................................................................................................................................................................................................................................................... Good news, I hope the results are great. This would be great news for all the stem cell companies and the science....................................................... ..................................................................................... Good luck in this rigged casino,

It's a Small World for Geron

I was reading about BioTime and found Dr. Michael West is CEO of BioTime. Dr. West was also the founder of Geron 20+ years ago. He left Geron a few years back. Now Dr. West wants to buy his baby back, nice. Also BioTime uses ACTCellerate technology, yea ACTC what a small world. I'm thinking there's a game being played here and the shareholders are not in on it...................................................................... .............................................................................................................................................................................. Good luck in this rigged casino,

Geron, ACTC, AAPL all down

AAPL is killing me, closed at $609.84. I need blowout earnings Oct 25th, a $65 run up for my calls to make money. ....................................................................................... ACTC down again at 0.0733. With no news we go lower. ...................................................................................... Geron closed at $1.44 down we go. The BXT offer is better than nothing, but it's close to nothing. I'll vote for it.......................................................... ....................................................................................... Good luck in this rigged casino,

Great News for Stem Cell Believers

9:05AM Geron: BioTime (BTX) issues open letter to shareholders of Geron; proposes transaction between Biotime Acquisition and Geron (GERN) 1.42 : BioTime (BTX) issued a letter to the shareholders of Geron regarding Geron's stem cell assets. BTX proposes Geron shareholders could own up to 45% of a new publicly traded co that will own the Geron stem cell assets, $40 mln of BioTime stock, certain BioTime stem cell assets, and shares of certain BioTime stem cell subsidiaries. Geron shareholders would also receive BioTime stock-purchase warrants presently valued at ~$13 mln. Geron would retain its cancer therapy business, including Imetelstat and GRN1005, and its cash and short-term liquid investments and Geron shareholders would continue to own 100% of the Geron cancer therapy business through their ownership of Geron stock. Through the "Stem Cell Transaction", Geron would transfer its stem cell assets to BioTime Acq, in exchange for which you along with the other Geron shareholders would receive shares of BAC common stock representing ~21.4% of the outstanding BAC capital stock. BioTime would contribute to BAC the following assets in exchange for the balance of outstanding BAC capital stock: $40 mln in BioTime common shares; Warrants to purchase BioTime common shares; Rights to certain stem cell assets of BioTime, and shares of two BioTime subsidiaries engaged in the development of therapeutic products from stem cells. .............................................................................................................................................................................................................................................................. This is all Geron is going to get. I'm going to take it. I believe in the science. I hope BioTime restarts the Phase 1 trials on spinal injuries soon. Just hope I live long enough to see results. Geron is up over $1.51. BTX was up a penny................ Good luck in this rigged casino,

I Stopped Waiting AAPL up big

AAPL up big on the news of Ipod mini, closed at $649.79 up $15.03 on 19.5 million shares. The three month avg. volume 15.8 million shares. Need $30 more for my calls. . . . Geron is going no where fast closing again at $1.37 shares. The volume only 339,014 shares. No market interest, need good news or we go lower. . . . ACTC down again at 0.0725 on 3.7 million shares. The three month avg. volume is 5.7 million shares. Need more good news on the Phase 1/2 trials or we will go lower.. . . . Good luck in this rigged casino,

Still Waiting Geron, ACTC and AAPL

AAPL should start it's run up into earnings Oct 25th. Closed up $5.05 at $634.76. Need $40s to made money on my 3 calls...................................................... ......................................................................................................................................................................................................................................................................ACTC down just a little at 0.0735. Need news soon if not we go lower. ......................................................................................................................................................................................................................................................................Geron closed flat at $1.37, volume was only 264,971. Needs news soon or we go under $1.............................................................................................................................................................................Good luck in thiis rigged casino,

Waiting for news AAPL, ACTC and Geron

Waiting on AAPL's, iPod mini on Oct. 23rd and earnings Oct 25th. I need a $35 run up for my calls to make money.................................................. ...................................................................................... ...................................................................................... Geron we need good news on the last four phase two trials. If the news is poor Geron is done as a company................................................................. ,............................................................................................................................................................................. ACTC more good news on trials, a partner, listing on the big broad.................... .................................................................................................................................................................................................................................................................... Good luck in this rigged casino,

AAPL up Geron and ACTC down

AAPL closed up $5.06 at $640.91 on 18.2 million shares. The three month avg. volume is 15.6 million Hoping for blow numbers on Oct 25th. ................................................................................................................................................................................................................................................................................................................................................................... ACTC was down a little at 0.074 on 4.4 million shares. The three month avg. volume is 6.2 million shares. Need more good news................................................ ..................................................................................................................................................................................................................................................................... Geron down 3 cents at $1.37 on 707,267 shares. The three month avg. volume is 1.6 month shares. Need good news on the last 4 remaining trials................................................................................. ..................................................................................................................................................................................................................................................................... Good luck in this rigged casino,

GE Healthcare exercises option to Geron's cellular assay patents

08 October 2012 GE Healthcare exercises option to Geron’s cellular assay patents Agreement covers intellectual property relating to stem cell-based technologies for drug discovery and predictive toxicity screening CHALFONT ST. GILES, UK – 8 October 2012 – GE Healthcare, the healthcare business of GE (NYSE: GE), announced today that it has expanded its 2009 license agreement with Geron Corporation for the development of cellular assays and models derived from embryonic stem cells (ESC’s) for use in drug discovery and toxicity screening. Under the terms of the expanded license, GE Healthcare obtains exclusive global rights to Geron’s intellectual property and know-how for the development and sale of cellular assays derived from induced pluripotent stem cells (iPS). Financial terms were not disclosed. GE Healthcare is pioneering the development of human cell-based assays and models for use in drug discovery and predictive toxicity screening. As the worldwide pharmaceutical industry seeks to reduce the cost of drug development and to bring more effective, safer drugs to market, the availability of more biologically relevant and predictive cell models is becoming increasingly important. In 2010 the company launched CytivaTM cardiomyocytes (human heart cells), stem cell-based assays that are already helping pharmaceutical companies develop safer medicines by identifying - much earlier in the discovery process - drug candidates that show toxic effects. The company also plans to launch Cytiva hepatocytes (liver cells) for toxicity testing, and recently announced a collaboration with the Beijing Genomic Institute aimed at understanding the underlying genetic variation between ethnically diverse stem cell lines.................................................................................. ....................................................................................... Dr Amr Abid, General Manager, Cell Technologies, GE Healthcare Life Sciences said, “Expanding our agreement with Geron is a significant step forward and will help us realise our vision of bringing the benefits of stem cell derived assays and models to pharmaceutical and cell science research. In the immediate term it will allow us to accelerate the development of new technologies and products for our customers in drug discovery. Longer term, by taking a licence from GE Healthcare, the wider industry will also benefit from the ability to use key intellectual property without violating patent rights. This clarity and freedom to operate will, I believe, do much to advance the use of stem cell based assays in drug discovery................................... This is great news and Geron is down, but I think this news slowed Geron drop. Also Geron filed a 8-K, which is a sales agreement between Geron and MLV & Co. for up to $50 million in shares. Still Geron closed down 5 cents at $1.41 on only 542,024 shares. The three month avg. volume is 1.6 million shares. ........................... AAPL closed down $2.32 at $635.85 on almost 30 million shares. The three month avg. volume is 15.7 million shares. I think we're done going down till earnings on the 25th. ...................................................................................... ACTC closed under 8 cents on 11.5 million shares. The three month avg. volume is 6.2 million shares. I don't know why this company is down the news the day before was good. ......................................................................................... Good luck in this rigged casino,

ACTC great news on Stargardt's disease trials

Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the Data and Safety Monitoring Board (DSMB), an independent group of medical experts closely monitoring the Company’s three ongoing clinical trials, has authorized the Company to move forward with enrollment and treatment of second and third additional patients with Stargardt’s macular dystrophy (SMD) in the second patient cohort of its U.S. trial for the condition. Additionally, the DSMB has authorized the Company to treat all three patients in the second cohort of its European trial for SMD. The UK Medicines and Healthcare products Regulatory Agency (MHRA) recently approved a protocol modification to the DSMB review, streamlining the process, allowing the company to treat the first patient in a new cohort if the DSMB has allowed this in the US study, and once clearance has been received in the US trial to treat the next two patients in the US cohort. This would also allow for treatment of the UK patients without an additional review by the DSMB. Moreover, according to the protocol for both trials, each patient in the second cohort will be injected with 100,000 human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells, up from 50,000 in the first cohort. “This authorization to treat the next five patients in the second, higher-dosage cohort in both our clinical trials for SMD represents a significant step forward for our clinical programs,” commented Gary Rabin, chairman and CEO of ACT. “We are also encouraged with the MHRA’s approval of the DSMB’s streamlined review process. Clearly this has the potential to help accelerate the pace of our European trial.” ACT is conducting three clinical trials in the U.S. and Europe using hESC-derived RPE cells to treat forms of macular degeneration, SMD and dry age-related macular degeneration (dry AMD). Each trial will enroll a total of 12 patients, with cohorts of three patients each in an ascending dosage format, from 50,000 hESC-derived RPE cells in the first patient cohort to 200,000 in the last and final cohort. These trials are prospective, open-label studies, designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation into patients with dry-AMD or SMD at 12 months, the study’s primary endpoint. “We are eagerly anticipating treating these final two patients in the second cohort of our U.S. trial for SMD, and all three patients in the second cohort of our E.U. trial,” commented Robert Lanza, M.D., ACT’s chief scientific officer. “We are encouraged by the preliminary data in the first patient in this second, higher-dosage cohort and look forward to gathering more data.” Further information about patient eligibility for ACT’s SMD studies in the U.S. and E.U. as well as its dry AMD study are available at www.clinicaltrials.gov, with the following Identifiers: NCT01345006 (U.S. SMD), NCT01469832 (E.U. SMD), and NCT01344993 (dry AMD).........................................................................AAPL down again, so I bought 4 more shares. I need a $50 run for my calls to be above water. ..................................................................................... Good luck in this rigged casino,

AAPL, ACTC and Geron all down again

Bad Day at Black Rock, great movie, somes up Friday. .................................. .............................................................................................................................................................................. AAPL down $14.21 to close at $652.59 on 21.2 million shares. The three month avg. volume is 15.3 million shares. I bought and sold one AAPL call. I have 3 AAPL calls, two at Feb 2013 $685 and one at Feb 2013 $690. Need about $20+ run to made some money. .....................................................................................................................................................................................................................................................................ACTC closed down a little at 0.07 on 8 million shares. The three month avg. is 6 million shares. Need good news or we continue down..................................... ..................................................................................................................................................................................................................................................................... Geron down, down, down we go. Closed at $1.41. I'm thinking the big boys are running Geron down, then will run it back up before Dec 5th, when Geron tells us how the Phrase two trails are going. Just like they did before Geron give us the bad news on two of the Phase two trials. So if this happens will sell some and write a few covered calls.................................................................................................................................................................................................................................................................Good luck in this rigged casino,

ACTC, AAPL and GERON all down

Not good, all three stocks down on a up day............................................ .............................................................................................................................................................................. AAPL down $4.65 to close at $666.80 on 13.1 million shares. Bought a $685 Feb 2013 call and then sold it, made a little money. Then bought it back again at the end of the trading day. AAPL still is the best company out there............................. .............................................................................................................................................................................. ACTC down a little again at 0.0725 on 9.3 million shares. The 10 day avg. volume is 6.2 million shares. With no news we go lower........................................... .............................................................................................................................................................................. Geron closed down 3 cents at $1.59 on only 503,531 shares. The 10 day avg. is 1.2 million shares. With no news we go lower............................................... .............................................................................................................................................................................. Good luck in this rigged casino,

Geron and ACTC going nowhere

Geron down again to $1.62 on only 570,000 shares. The three month avg. volume is 1.6 million shares. No news, no interest............................................... .............................................................................................................................................................................. ACTC down again to 0.0727 on 5.5 million shares. The three month avg. volume is 6 million shares. Need news or we go lower.......................................... ..................................................................................................................................................................................................................................................................... AAPL up $10.14 to close at $671.45 on 15.1 million shares. The three month avg volume is 15.1 million shares. I bought two $690 call for Feb 2013, on Monday. Sold one today made $208 and will sell the 2nd this week I hope, need $7 more dollars. Earnings Oct 15th ................ ........................................................... ...................................................................................................................................................................... Good luck in this rigged casino,

Write this down I did a good trade with AAPL

WOW sold my $690 Call Thursday and AAPl went down $14.22 today. May buy that call again Monday. AAPL closed at $667.10 on 19.1 million shares. The three month avg. volume is 15 million shares. Down because of the mapping fiasco. AAPL is still the best company out there............................................................. ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, ....................................................................................... ACTC down a little at 0.0763 on 4.5 million shares. Needs news........................ ...................................................................................... ...................................................................................... Geron added Susan M. Molineaux and Daniel M. Bradbury to its board of directors. Why? I hope it's to made us shareholders some money. We will see. Geron closed down 3 cents at $1.71 on only 928,853 shares....................................................... ..................................................................................................................................................................................................................................................................... Good luck in this rigged casino,

AAPL up big, Geron up a little

LOVE AAPL up $16.14 to closed at $681.32 on 21.2 million dollars. The three month avg. volume is 14.6 million shares. I sold my $690 Feb 2013 Call at $45, I bought at $40, made $480. Yea, I should have held it a little longer. But an old investor once said any time you can make money on an option do it. ........................................... .............................................................................................................................................................................. ACTC closed down just a little at 0.0769 on 4.5 million shares. The three month avg. volume is 6 million shares. Need good news............................................ .............................................................................................................................................................................. Geron closed up 2 cent at $1.74 on 1.2 million shares. The three month avg. volume is 1.6 million shares. Waiting for news on the last Phase 2 trials using imetelstats. The first 2 trials were a disaster. The last two trials are on the side effects of imetelstats that might be helpful. Geron said at the end of Dec 2012 will have results. ......................................................................................................................................................................................................................................................................Good luck in this rigged casino,

Geron up, AAPL down

AAPL down, I added 5 big shares at $667 and bought a Feb 2012 $690 Call for $4,000. Will by a few more shares if the share price goes down under $660.................... ...................................................................................... Geron up a little, waiting on news..................................................... ....................................................................................... ACTC flat need some news,.............................................................. .............................................................................................................................................................................. Good luck in this rigged casino,

Geron , ACTC, AAPL all down

Geron closed down 5 cents at $1.70 on 1.2 million shares. The three month avg. is 1.6 million shares. We still around here without any good news........................................................................................................................................................................... ACTC down under 8 cents at 0.0763 on 4.6 million shares. The 3 month avg. is 6.1 million shares. Need goods news or we go lower......................................................................................................................................................................... AAPL $673.53 down $17,25 on 18.5 million shares. The three month avg. volume is 14.4 million shares. Going to buy a few shares Thurs. We could see $650.......................................................................................................................................................................... Good luck in this rigged casino,

AAPL down

AAPL down to close at $690.79 on 22.7 million shares. The three month avg. volume is 14.1 million shares. I think I may buy a few shares or buy a Jan 2014 $800 call, but that's a $5,600 bet................................................................... ACTC down a little under 8 cents at 0.0785 on 6.6 million shares. The three month avg. volume is 6.1 million shares. May add a few thousand shares. Geron closed at $1.75 on 1.5 million shares. Thinking we stay here for a few weeks until there is news, hopefully good............................................... Good luck in this rigged casino,

Geron filed Form 3 with SEC

Geron was up and closed at $1.765 on 2 million shares. The three month avg. volume is 1.6 million shares. Form 3 is for Executive Vice President Andrew J. Grethlein who will be getting 600,000 shares of Geron. Here's his deal: 75,000 shares on March 17, 2013, the rest of the 525,000 shares in a series of 42 equal monthly installments commencing March 17, 2013. That's a good deal and you know he's going to be working hard to get the stock price up by March 17, 2013 and every month after that........................ ACTC closed down a little at 0.08 on 15.6 million shares. The three month avg. volume is 5.9 million shares. Great volume but not great price action. Need more great news .. ........................................................................................ AAPL up over $700 to close at $700.09 on 19.4 million shares. The three month avg. volume is 14 million shares. .......................................................... Good luck in this rigged casino,

ACTC up on good news

The last blog, ACTC got $35 million and that will keep them in business for 2 more years. ACTC closed up a little at 0.0840 on 38.5 million shares. The three month avg. volume is 5.5 million shares. Great volume not much of a price move up. Still need more good news on the Phase1/2 trials ............................................................................................................................................................................................................................................................. Geron was up one cent at $1.71 on 3.8 million shares. The three month avg. is 1.5 million shares. I think we stay around $1.50-$1.80 until we get some good news..................................................................................... AAPL closed down little at $698.70 on 12 million shares. The three month avg. volume is 14 million............................................................................. ........................................................................................ Good luck in this rigged casino,

Good News for ACTC

Advanced Cell Technology Secures New $35 Million Funding Commitment from Lincoln Park Capital ................................................................................. Sep 20, 2012 08:30:01 (ET).............................................................. MARLBOROUGH, Mass., Sep 20, 2012 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that it has entered into a $35 million common stock purchase agreement with Lincoln Park Capital Fund, LLC ("Lincoln Park Capital") a Chicago-based institutional investor. Upon executing the agreement, Lincoln Park Capital made an initial purchase of $800,000 in common stock from the Company at a purchase price of $0.08 per share. The Company has agreed to file a registration statement with the U.S. Securities & Exchange Commission ("SEC") covering the shares that may be issued to Lincoln Park Capital under the terms of the common stock purchase agreement. After the SEC has declared the registration statement related to the transaction effective, the Company has the right at its sole discretion over a period of three years to sell up to an additional $34.2 million of its common stock to Lincoln Park Capital under the terms set forth in the agreement. Proceeds from this transaction will be used to fund the company's clinical activities, including its three ongoing Phase I/II clinical trials for forms of macular degeneration, for development of its other clinical activities, and for general corporate purposes............................................................................... "We are most pleased about this financing agreement, as it has a number of notable benefits for the company," commented Gary Rabin, chairman and CEO of ACT. "Lincoln Park Capital is an excellent partner for us with a great track record and a long-term commitment to the life sciences field. This transaction offers the Company a very cost efficient and readily available form of financing. The $35 million available under the agreement equates to more than two years of funding for the Company, even assuming no other sources of capital. It was a priority for us to complete a new financing by year-end, as we never again want to be in a position to have to go looking for capital from a position of distress or weakness. This agreement strengthens our balance sheet allowing us to focus on advancing our clinical programs, pursuing strategic partnerships, and other long-term objectives.".......................................... Under the terms of the agreement, there are no upper limits to the price that Lincoln Park Capital may pay to purchase the Company's common stock and this transaction in no way impedes or changes the Company's goal of completing a reverse split and national listing. The Company plans to continue pursuing its stated corporate milestones of achieving a national listing and pursuing the optimal corporate partnerships for its programs. The Lincoln Park financing commitment simply strengthens the Company's balance sheet and makes available an additional source of funding. In consideration for entering into the $35 million agreement, the Company has issued additional shares to Lincoln Park Capital as a commitment fee. Under the terms of the agreement, Lincoln Park Capital has covenanted not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of the Company's shares of common stock. Josh Scheinfeld, Managing Member of Lincoln Park Capital, said, "We are very pleased to be entering into this agreement with Advanced Cell Technology. We at Lincoln Park have been following the progression of the Company over the past several years and are excited to be making this investment. We are impressed by the Company's technology and the clinical data that has been published to date." Additional details regarding the financing are included in a Current Report on Form 8-K filed on September 19, 2012 by the Company with the Securities and Exchange Commission. About Advanced Cell Technology, Inc. Advanced Cell Technology, Inc., is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit www.advancedcell.com .

Geron closed up 16 cents

Well, still no news on why the run up on good volume. Any move up is good. Geron closed at $1.67 on 3.6 million shares. The three month avg. is 1.5 million shares. ............ ACTC was down a little at 0.08 cents on 3.7 million shares. The three month avg. volume is 5.5 million shares. Need some good news.............................................. AAPL up just a little at $702.10 on 11.6 million shares. Volume going down could mean price as peaked for now................................................................ Good luck in this rigged casino,

Geron up 20 cent on 3+ million share

Once burned twice shy, baby. All the signs say great news is coming soon, just like the last run. I'm just going to wait, have 6,000+ shares not covered so I'm getting a good ride from this run. Just hope it's some thing great and that's all it is hope.................................................................................... Good luck in this rigged casino,

Geron up 13 cent on good volume

Geron is at $1.67 on over 2.2 million shares. I can't find anything for the price increase. With Geron there is always doubt but as long as they're in business there's a chance. I have 40 covered calls [that's 4,000 shares] at $2, half for Oct and half for Mar 2013. Hoping for good news after Oct 19th. Good luck in this rigged casino,

ACTC up Geron up AAPL over 700

Great day! Geron hired new attorneys for the Patent case, so maybe they will appeal. Geron closed up 11 cents at $1.54 on almost 3 million shares. The three month avg. volume is 1.5 million shares. I like the volume with the price, is there some good news coming. With Geron there is always doubt but as long as they're in business there's a chance. ACTC up over 8 cents to close at 0.081 on 6.2 million shares. The three month avg. volume is 5.5 million shares. Hoping for some good news soon. AAPL up over $700 YEA BABY, closed at $701.91. Good luck in this rigged casino,

ACTC down on settlement

ACTC was down under 8 cent at 0.078 on 15 million shares. The news was a settlement with Alpha Capital of $500,000 which was paid with 34,285,714 shares. I may buy a few more shares. Geron hired Adrew J. Grethein PhD, he will oversee the Company's manufacturing and quality functions. Let's hope thet are seeing some positive results on GRN1005. Geron closed up 2 cents at $1.43 on 1.5 million shares. AAPL up again closing in on $700. It closed at 699.78 on 13.7 million shares. The three month avg. volume is 14 million shares. We'll hit $750 soon. Good good in this rigged casino,

ACTC can remove embryonic stem-cell without destroying

ACT uses an embryonic stem-cell-removal technique that doesn’t destroy anything: It removes a single cell from embryos that are in the eight-cell stage--in other words, extremely early on. It’s identical to what’s done in in-vitro fertilization clinic for genetic testing of diseases like Tay-Sachs and Huntington’s Disease. "It’s a non-destructive, non-harmful method of extracting these cells and creating embryonic stem cells. There are thousands of babies born every year having this exact kind of genetic testing done," says ACT CEO Gary Rabin.
ACTC closed down a little at 0.082 on 8.4 million shares. The three month avg. volume is 5.2 million shares.

AAPL closed up $8.30 at $691.28 on 21.4 million shares. The three month avg. volume is 14 million shares.

Poor, poor Geron closed down just a little at $1.41 on 2.6 million shares. The three month avg. volume is 1,440,810 shares.

Good luck in this rigged casino,

Geron selling the HESC portfolio very soon

That's the rumor on Yahoo Message Board. Some folks are says that's why the share price is going up. I don't think Geron will get much money up front. Chip the CEO said so a while back. Geron closed up 8 1/2 cents at $1.415 on 3.7 million shares. The three month avg. volume is 1,351,790 shares. I like the volume, we could go up to $1.75, but I think more bad news is coming.

ACTC closed up a little at 0.0855 on 3.5 million shares. The three month avg. volume is 5.1 million shares.

AAPL was up $13.19 to close at $682.98 on 21.3 million shares. The three month avg. volume is 13.7 million shares.

Fed's stimulus move ignites Wall Street. That's the headline, and we will go higher and if the economy does not improve soon 3-6 months we will drop like a stone.

Good luck in this rigged casino,

Dead cat bounce for Geron?

Maybe!  I sold 20  $2 Mar 2013 covered calls for 20 cents will lose $2 thousand if there are called home in Mar 2013. Geron up to $1.40 on good volume. Again there's a small chance the last two Imeteltat trials may have good results just because it's betting on the side effects of the drug not the effect of the drug. The GRN1005 will make or break this company. Again I will keep 3-5 thousand shares until the results are known. I have sold 50 covered calls [that's 5 thousands shares] leaving me about 8 thousand shares not covered.

Good luck in this rigged casino,

Geron up AAPL up

Dead cat bounce for Geron? Maybe. With only GRN1005 and maybe a small, very small chance that the last two trial with imetelstat may work I can't put much hope in this company. So I sold 1000 shares at $1.30 for a $400 loss and sold 10 $1 covered calls for Mar 2013 for 55 cents, that would be a $1500 loss. I'm still going to keep 3-5 thousand shares till the GRN1005 trials are over and results are known. I can't believe a Geron could be 100% wrong on everything they have done. Even a blind squirrel finds a nut once in a while.
Geron was up 7 cents to close at $1.33 on 2.8 million shares. The three month avg. volume is 1.3 million shares.
Remember the last two imetelstat trial are going for the side effects of imetelstat that helps lower the red blood count, [I may have that a little wrong but it's the side effect of imetelstat, Geron is hoping that will work].

ACTC,  I thought was going to move up, but it closed down a little at 0.0845 on 9.4 million shares. The three month avg volume is 5 million shares. ACTC is the future in bio-tech.

AAPL iPhone 5 and it's up 9.20 to closed at $669.79 on 24.7 million shares. We go higher.

Good luck in this rigged casino,

Geron down and ACTC up over 9

Geron was down only two cent to close at $1.26 on 4.1 million shares. I sold 1000 shares at $1.26, will sell more and will sell some covered calls at $1.00. It's dark days ahead for Geron. I was surprised it didn't close lower. New 52 week low $1.23.

ACTC was up over 9 cents at 0.0914 on 15 million shares. I think we go higher.

Good luck in this rigged casino,

Geron down 55% closed at $1.28

The worst thing that could have happened,,,,,,,HAPPENED. The people being treated with the imetelstate were dying sooner then the people not taking imetelstate. It can't get worse than that. So Geron stopped the breast cancer trial and they stated the small cell lung cancer trial was not showing much improvement. So that means only two trials left using imetelstate, only a miracle will save these trials. Now that leave the two GRN1005 trials that will have results sometime in the 2Q of 2013. Maybe that will save Geron. My confidence in Geron is totally shot. I will be slowly selling my shares down to around 3,000 shares.
Geron closed down 55.86% at $1.28 on 19.5 million shares. The three month avg. volume is 976,773 shares.

Good luck in this rigged casino,

Disaster of the highest order for GERON

Geron Corp. (GERN, Trade ) shares fell 51%. The biotech firm said Monday that it's discontinuing its Phase II study of imetelstat in metastatic HER2-negative breast cancer because median progression-free survival was shorter than the comparison treatment.  I'm working tell I'm 70 or till I drop dead. Cry me a river.
DISASTER, DISASTER, DISASTER, DISASTER.

GOOD LUCK IN THIS RIGGED CASINO,

ACTC Sept 10th webcast

ACTC chairman and CEO Gary Rabin will be presenting at the 14^th Annual Rodman & Renshaw Global Investment Conference, Sept. 9-11 in New York. Mr. Rabin’s presentation will take place on Monday, Sept. 10, at 12:05 p.m. EDT, at the Waldorf Astoria. We need some good news.


Good luck in this rigged casino,

Geron new high again

Geron closed up 6 cents at $2.90 on 1.7 million shares. The new 52 week high is $2.99. The three month avg. volume is 967,411shares. What does the future hold for Geron? Here's my vision. Geron continues to $3.75-4.30. When Phase 2 oncology test results are announced in 4th quarter. With good news Geron spikes to $5.50-7.00. With good news in 1st quarter of 2013 on GRN1005. Geron spikes to $8-10. Shortly thereafter Geron is sold for $14-20.  Just a dream.

AAPL up again to close at $680.50 on 11.6 million shares. The three month avg. volume is 13.5 million shares.

ACTC closed up a little at 0.0828 on 3.1 million shares. The three month avg. volume is 4.7 million shares.

Good luck in this rigged casino,

Geron new high again

Geron was up to $2.98 so far today, which is a new 52 week high. Geron's around $2.95 now. The volume is not great, under 800,000 shares so far.  We're up from $1.71 on Aug 17th. to almost $3 today. Now think what will happen if the Phase two results are good. A guess would be a run to $6, maybe more and if Geron gets a partner, I can see $10. Down the road $20 with more good results. If the Phase two results are poor Geron trials under a $1. It's a big reward if I'm right. If I'm wrong I'll be crying me a river.

Good luck in this rigged casino,

ACTC to Present Sept 10th

MARLBOROUGH, Mass., Sep 07, 2012 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that ACT's chairman and CEO Gary Rabin will be presenting at the 14th Annual Rodman & Renshaw Global Investment Conference, Sept. 9-11 in New York. Mr. Rabin's presentation will take place on Monday, Sept. 10, at 12:05 p.m. EDT, at the Waldorf Astoria.
The presentation will be webcast live (link here) and the presentation slide deck will be available on the conference presentations section of the ACT website.
Should move share price up.

Good luck in this rigged casino,

Geron New 52 Week High

Geron closed up at $2.845 the new 52 week high is $2.88 on over 2 million shares. The three month avg. is 967,411 shares. Volume has been good and we keep going up. $3.00+  Next stop. If we keep going up on good volume I would say the Phase two trials are going to have good results and it's known by a few people who are buying.

ACTC closed down just a little 0.8018 on 2.5 million shares. The three month avg. volume is 4.8 million shares.

AAPL closed up at $676.27 on 14 million shares. The three month avg. volume is 13.6 million shares.

Good luck in this rigged casino,

Geron's CEO Chip was good

Geron's CEO "Chip" give a good presentation at the Stifiel Nicolaus Healthcare Conference. You can listen to and watch at there website. Geron closed down at $2.73 on 1.7 million shares. We also hit a new 52 week high of $2.83.  The three month  avg. volume is 933,738 shares. What I think from listening to "Chip" is the Breast Cancer phase two trial are going well [having good results the patients are living longer] because they where going to report results at the end of Dec 2012 and had to move it to 1st Q of 2013.  I think we will still go a little lower before Dec 2012. If it all works out in Geron's favor we will hit $5 by 2013. If not we will be under $2.

Good luck in this rigged casino,

Geron new 52 week high

Geron closed at $2.79 up three cents and hit a new 52 week high of $2.82. The volume was 1.6 million shares. The three month avg. volume is 908,797.  Geron's CEO "Chip" will speak Sept 5th Wed at 10:55 AM.  Hoping for something new.

AAPL up to close at $674.97 on 13 million shares. The three month avg. volume is 13.6 million shares.

ACTC closed up a little at 0.0829 on 3.9 million shares. The three month avg. 4.8 million shares.

Good luck in this rigged casino,

Seeking Alpha on Geron today

Geron (GERN) - Imetelstat: Following its consolidation in the oncology field, Geron is currently conducting four Phase II studies with Imetelstat, a first-in-class telomerase inhibitor targeted at solid tumors and hematological malignancies. One of Imetelstat's main advantages, which is derived from its mode of action, is that it could be suitable for treating a wide varaiety of tumors. Should results from the Phase II studies, expected during 2013, will prove efficacy this drug will become a strong candidate for a licensing deal.
The Phase two trials have to be good or Geron is done.

Good luck in this rigged casino,

ACTC Dr. Lanza to Deliver Opening Speech 4th Annual

ACT's Chief Scientific Officer Dr. Robert Lanza to Deliver Opening Keynote Address at 4th Annual Stem Cell Symposium in Singapore

Sep 4, 2012 08:30:02 (ET)

MARLBOROUGH, Mass., Sep 04, 2012 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that its chief scientific officer, Robert Lanza, M.D., will be delivering the opening Keynote Speech at the 4th Annual Stem Cell Symposium 2012, being held in Singapore, September 6-7. Dr. Lanza's presentation is titled "Pluripotent Stem Cells -- From Benchtop to Clinic."
With the theme, "Stem Cell Based Therapy," the symposium will have a particular focus on clinical trials and industrial application of stem cells. Sponsored by Stem Cell Society of Singapore (SCSS), the conference will include scientific presentations from key contributors from academic, clinical, and commercial organizations who are translating basic research on stem cells into therapeutics, with a focus on applying engineering technologies to provide medical solutions.
In their opening statement, the organizers state, "We are all keeping our 'fingers crossed' for ACT's success, which will also bring a big boost to the stem cell community."
Other topics of the conference include human induced pluripotent stem cells (hiPSCs), drug screening, adult and cancer stem cells, and stem cell therapies emerging from Asia, with presentations from Indian, Korean and Japanese regenerative medicine companies. There will also be a joint session with the International Society for Cellular Therapy (ISCT) covering important issues concerning the commercialization of stem cells, and addressing issues such as reimbursement, manufacturing, characterization, and clinical implementation issues unique to cell therapies.

Geron's CEO "Chip" will speak Wed at 10:55AM it will be webcast, should move the share price up or down. Geron has had a great run from $1.71 on Aug 17th to $2.76 today.

Good luck in this rigged casino,

Geron good run, but to soon

Biotech Geron (Nasdaq: GERN ) was perhaps the one stock rising for a reason, as an analyst offered a positive outlook on the cancer therapies it's developing, but the stock has been on the move for awhile now (up 60% over the past month) after a positive review two weeks ago on Seeking Alpha. I said at the time the treatments hold a lot of promise, but the results of midstage trials have some time to go before we see the actual outcome, so the spike in its shares now seems a bit premature. I'd say the same for the current run-up based on the rosy view offered up by the Wall Street analyst.

Good luck in this rigged casino,

What a great week for Geron

Geron closed up 13 cents to close at $2.76 on 1.9 million shares. The three month avg. volume is 894,148 shares. Geron was at $1.71 on Aug 15th what a great run on no news. Sept 5th at 10:55AM Chip the CEO will speak. It will be webcast. I'm hoping for good news. We will see. The secondary offering is a worry,[if there is one] I got burned on the last one. That's why I sold some covered calls just in case.

ACTC closed down a little at 0.0803 on 2.6 million shares. The three month avg. volume is 5 million shares.

AAPL closed up a little at $665.24 on 11.4 million shares. The three month avg. volume is 13.8 million shares.

Good luck in this rigged casino,

Geron up big again

Geron closed up 22 cents at $2.63 on 3.4 million shares. The three month avg. volume is 849,533 shares.
Geron to present at the Stifel Nicolaus Healthcare Conference Sept. 5 Wed. at 10:55AM.  This will be very interesting. If Chip the CEO says anything new and good, we go over $3. If it's more of the same we head slowly to $2.

Good luck in this rigged casino,

Geron up 24 cents pre-market wow

Geron  shares rose 11%. Stifel Nicolaus analysts started the biotech company with a buy rating on Thursday morning. Target $4.
Up 24 cents just on a upgrade. My almost 9,000 shares love it. My 4,000 covered shares do not, but that's ok. We still need news, by all the signs it should be good. BUT I've been doing this for 40 years, it still could be a pump and dump, a secondary offering is coming.

Good luck in this rigged casino,

Sienna's telomerase based Cancer diagnostics test kit

• Everyone knows about the Imetelstat trial results but few know about the large scale testing of Sienna's telomerase based Cancer diagnostics test kit. The results of the testing is expected in December. The pre large scale testing results were the test was 97% effective at catching cancer early and there were no false positives for this non invasive test kit. Many do not also know Geron is Sienna Cancer Diagnostics largest share holder.

  This would be great for Geron, they would get more income from the selling of the Cancer diagnostics test kits through royalties and the increase in Sienna's value.

  Geron closed down 3 cents at $2.41 on 1,379,886 shares. The three month avg, is 849,533 shares. Still with no real news we should go a little lower, maybe $2.10.

  
  

  ACTC was down a little at 0.08 on 1.8 million shares. The three month avg. is 5 million shares. Waiting for news.

  
  

  AAPL closed down just a little at $673.47 on 7.2 million shares. The three month avg. volume is 13.9 million shares. Still the best company out there.

  
  

  Good luck in this rigged casino,

GRN1005 trials updated yesterday on Clinical Trials . gov

Geron has added more sites for its GRN1005 trials. It's all good. I'm surprised the price is still around $2.40. Still think we go to $2.10 with no real news on results of Phase 2 trials.

Good luck in this rigged casino,

Geron up big again

Geron closed up 14 cent at $2.44 on 1.3 million shares. The three month avg. volume is 832,770 shares. Why the run from $1.71 on Aug. 15th to $2.55 on Aug 28th? I have no real answer, I sold 40 covered calls at different prices and months just because the run may be all bs. Why? Geron needs money they will do secondary offering soon. The last one I lost half my money on.  JPM made 50 cents a shares selling the offering. At $1.71 a share they would have to sell the secondary at $1.50 or less a share, with JPM fees that would leave Geron with $50 million or less [that's if they sold 50 million, they have the ok to sell 100 million shares] So I think they are going for $2.50 a share. That would mean a run to $3 plus, then a secondary offering at $2.50 a share, maybe 100 million shares. That would $200 million clear and would do Phase 3 with the help of a partner.  That's my guess on the run, I hope [with my 9,000+ uncover shares] I'm wrong.
We will see.

ACTC closed down a little but still above 8 cents at 0.0808 on 2.3 million shares. The three month avg. volume is 5 million shares. Need god news.

AAPL give back a little to close at $674.80 on 9.4 million shares. The three month avg. volume is 14.1 million shares.

Good luck in this rigged casino,

ACTC up over 8

ACTC closed at 0.0809 on 4.9 million shares. The three month avg. volume is 4.9 million shares.

AAPL up  big to close at $675.68 on 15.1 million shares. The three month avg. volume is 14.1 million shares. We go higher.

Geron closed flat at $2.30 on 1.4 million shares. The three month avg. volume is 812,400 share. With the good article on Seeking Alpha today, you would think Geron would be up. I think we go down to $2.10 soon if there is no more good news. Will buy back my Oct $2 calls if it does.

Good luck in this rigged casino,

Geron good article Seeking Alpha

This was in Seeking Alpha today: Consider These 3 Biotech Stocks for Potential Growth.
Geron was established in 1990 and completed its IPO in 1996. It is unusual to see a biotech company which has survived for that length of time without a product on the market. Most biotech companies in this position either fail or get acquired. Geron started out by focusing on stem cell treatments as well as oncology treatments, but decided to abandon stem cell research in 2011 due to the high cost of working on both, and decided to focus solely on oncology. It is working on the disposal of its stem cell assets, but there has been no progress reported so far. The company has two oncology drugs under development which have the potential to revolutionize cancer treatment if they are successful. The company has six Phase 2 trials currently underway.
The company's first, and most advanced drug, is called Imetelstat, a telomerase inhibitor which is currently in Phase 2 trials. Telomerase is the enzyme that enables cells to divide indefinitely without becoming unstable, thus allowing tumors to grow. There is plenty of scientific evidence to indicate that the enzyme is a key factor in the development of cancer. Geron is not the only company working on telomerase inhibitors, but it is the most advanced. Its strategy for cancer treatment is to stop or inhibit the growth of tumors. Imetelstat is currently in trials for the treatment of four different types of cancer, including breast cancer, NSCLC (non-small cell lung cancer) for solid tumors, multiple myeloma, and essential thrombocythemia for malignancies related to hematology. The data from all four trials is expected to become available over the next twelve months.
GRN1005 is an LRP-directed peptide drug combination aimed at treating brain cancer, which is currently very difficult to treat, because existing cancer drugs cannot penetrate the barrier between circulating blood in the body and the fluids of the brain. GRN1005 uses the LRP-1 transport mechanism, which uses a particular protein to bypass the blood-brain barrier and deliver cancer drugs to the brain. GRN1005 is now in Phase 2 trials to test the effectiveness of treatment in breast and lung cancer that has spread to the brain.
Geron's approach to oncology is unique, and positive results from any of the trials could potentially boost the price of the stock. Conversely, there is also limited protection for the stock price because of the number of trials that are in progress simultaneously. Additionally, failure in one trial may be construed as a possible failure in other trials utilizing the same drug which could be catastrophic for the share price. I urge risk tolerant investors interested in Geron to conduct further research and be prepared to hold for twelve months or longer.

I've beed staying this for months. If Geron hits I'm rich if they miss, it's work till I drop.

Good luck in this rigged casino,